Tag: OGXI

Finance

Healthcare losers: Corcept Therapeutics Incorporated (NASDAQ:CORT), OncoGenex Pharmaceuticals (NASDAQ:OGXI), Anika Therapeutics (NASDAQ:ANIK), Oncomed Pharmaceuticals (NASDAQ:OMED), Cesca Therapeutics (NASDAQ:KOOL)

Corcept Therapeutics Inc (NASDAQ:CORT) Director G Leonard Baker, Jr. bought 103,386 shares of the stock in a transaction that occurred on Wednesday, June 11th. The stock was purchased at an average cost of $2.32 per share, for a total transaction of $239,855.52. Following the completion of the transaction, the director now directly owns 578,389 shares of the company’s stock, valued at approximately $1,341,862. Corcept Therapeutics … Continue reading Healthcare losers: Corcept Therapeutics Incorporated (NASDAQ:CORT), OncoGenex Pharmaceuticals (NASDAQ:OGXI), Anika Therapeutics (NASDAQ:ANIK), Oncomed Pharmaceuticals (NASDAQ:OMED), Cesca Therapeutics (NASDAQ:KOOL)

Richard Atkins
Finance

Healthcare Decliners: SunLink Health Systems, Inc. (NYSEMKT:SSY), Recro Pharma Inc (NASDAQ:REPH), OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI), Retrophin Inc (NASDAQ:RTRX)

SunLink Health Systems Inc. (NYSEMKT:SSY) said that net loss for the third-quarter ended March 31, 2014 widened to $964,000 or $0.10 per share, from $186,000 or $0.02 per share last year. Loss from continuing operations for the quarter was $911,000 or $0.10 per share, compared to a loss from continuing operations of $197,000 or $0.02 per share in the prior year. Quarterly operating loss from … Continue reading Healthcare Decliners: SunLink Health Systems, Inc. (NYSEMKT:SSY), Recro Pharma Inc (NASDAQ:REPH), OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI), Retrophin Inc (NASDAQ:RTRX)

Richard Atkins
BioTech

Biotech Early Movers: OncoGenex Pharmaceuticals Inc(NASDAQ:OGXI), Agenus Inc(NASDAQ:AGEN), Athersys, Inc.(NASDAQ:ATHX)

OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) shares plunged more than 48% pre-market after the company said results from its Phase 3 SYNERGY trial to add custirsen to standard first-line treatment of docetaxel/prednisone in men with metastatic prostate cancer failed to meet primary endpoints. The stock which was halted from trading ahead of the news, recently changed hands at $5.00, off an earlier low of $4.25. The shares … Continue reading Biotech Early Movers: OncoGenex Pharmaceuticals Inc(NASDAQ:OGXI), Agenus Inc(NASDAQ:AGEN), Athersys, Inc.(NASDAQ:ATHX)

Colin Pettis
Finance

Healthcare Bullish Stocks: Biota Pharmaceuticals (NASDAQ:BOTA), OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI), Vermillion (NASDAQ:VRML), Genetic Technologies (NASDAQ:GENE)

Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) presented an update on the company at the 26th Annual ROTH Conference at 12:30 p.m. PDT, March 11, 2014, at The Ritz-Carlton, Dana Point in California. Biota Pharmaceuticals Inc (NASDAQ:BOTA) stock performance was 10.15% in last session and finished the day at $6.62. Traded volume was 449,674 million shares in the last session and the average volume of the stock remained … Continue reading Healthcare Bullish Stocks: Biota Pharmaceuticals (NASDAQ:BOTA), OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI), Vermillion (NASDAQ:VRML), Genetic Technologies (NASDAQ:GENE)

Jason Knox
BioTech

Biotech Stocks Touching New Highs: Northwest Biotherapeutics (NASDAQ:NWBO), OncoGenex Pharmaceuticals (NASDAQ:OGXI), Emergent Biosolutions (NYSE:EBS), Xencor (NASDAQ:XNCR)

CRT Capital Thursday morning ratings report included a coverage initiation by analyst Arlinda Lee on Oncogenex Pharmaceuticals (NASDAQ: OGXI) with a Buy rating and price target of $20. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) rose 8.88 percent to $13.85 yesterday on volume of 483,342million shares. The intra-day range of the stock was $12.61 to $13.95. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) has a market capitalization of $203.70million. Emergent Biosolutions … Continue reading Biotech Stocks Touching New Highs: Northwest Biotherapeutics (NASDAQ:NWBO), OncoGenex Pharmaceuticals (NASDAQ:OGXI), Emergent Biosolutions (NYSE:EBS), Xencor (NASDAQ:XNCR)

John Meady
Finance

Hot Watch List: OncoGenex Pharmaceuticals (NASDAQ:OGXI), Enanta Pharmaceuticals (NASDAQ:ENTA), Cheesecake Factory Incorporated (NASDAQ:CAKE), Randgold Resources Limited (NASDAQ:GOLD), OvaScience, Inc. (NASDAQ:OVAS)

On 7 AUG OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) announced second quarter 2014 financial results. Revenue for the three and six months ended June 30, 2014 was $4.9 million and $16.7 million, respectively.  This compares with $6.3 million and $11.4 million, respectively, in the same periods in 2013. Revenue earned in the second quarter of 2014 consists of reimbursable clinical trial, manufacturing and preclinical costs incurred by … Continue reading Hot Watch List: OncoGenex Pharmaceuticals (NASDAQ:OGXI), Enanta Pharmaceuticals (NASDAQ:ENTA), Cheesecake Factory Incorporated (NASDAQ:CAKE), Randgold Resources Limited (NASDAQ:GOLD), OvaScience, Inc. (NASDAQ:OVAS)

Ryan Holtz